Biopharmaceutical company BerGenBio ASA (OSE:BGBIO) announced on Tuesday that the first patient has been enrolled in a clinical trial evaluating bemcentinib, its AXL kinase inhibitor, in combination with pacritinib, a JAK2 inhibitor.

The trial, sponsored by the Mays Cancer Center at UT Health San Antonio, will investigate this combination therapy in patients with lung adenocarcinoma.

Pacritinib is marketed in the United States as VONJO and is owned by biopharmaceutical company Swedish Orphan Biovitrum AB (Sobi) (STO:SOBI).

The study is funded by a grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).